Spotlight on Family Medicine
Emergence of Biologics in Eosinophilic Asthma: A Wheel of Knowledge Challenge!
StartActivity Details
0.5 ABIM MOC Point(s)
Expires: September 29, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is allergists, pulmonologists, primary care physicians, and other health care professionals involved in the management of patients with eosinophilic asthma.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Employ understanding of the prevalence and pathophysiology of eosinophilic asthma, including the role of eosinophils as a biomarker in the management of asthma.
- Apply knowledge of mechanisms of action, frequency, routes of administration, and clinical evidence regarding the safety and efficacy of biologic therapies for the management of eosinophilic asthma.
Activity Description
In this Wheel of Knowledge Challenge interactive quiz, your knowledge will be tested on biologic therapy options for patients with eosinophilic asthma, including mechanisms of action, frequency, routes of administration, and clinical evidence regarding safety and efficacy. Your hosts will also discuss the prevalence and pathophysiology of eosinophilic asthma and the role of eosinophils as a biomarker in asthma management.
Statement of Educational Need
An increasing body of evidence continues to define the presence of severe asthma subtypes that do not respond to conventional therapies. Eosinophilic asthma is an often-severe subtype of asthma, predominantly driven by eosinophilic airway inflammation. Clinical practice guidelines recommend phenotypic assessment and consideration of select add-on biologic therapy for eosinophilic asthma. Biologic therapies that modulate the interleukin (IL)-5 and IL-4/13 signaling pathways offer important maintenance therapy options for patients with eosinophilic asthma inadequately controlled on standard therapy. Awareness of the latest evidence-based strategies for managing eosinophilic asthma will better enable health care professionals to tailor an individualized, targeted treatment approach.
Faculty
Associate Professor, Medicine-Pulmonary
Director, Airways Clinical Research Center
Member, Vice Chair of Research Group
Baylor College of Medicine
Director, Asthma and COPD Clinic
Ben Taub Hospital
Houston, TX
Disclosure:
Consulting Fee: Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi, Teva
Contracted Research: AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Gossamer Bio, Novartis, Sanofi
Professor, Pulmonary & Critical Care Medicine
Director, Mary Parkes Center for Asthma, Allergy & Pulmonary Care
University of Rochester
Rochester, NY
Disclosure:
Contracted Research: GlaxoSmithKline
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.5 Medical Knowledge MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s responsibility
to submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This educational activity is supported by an educational grant from GlaxoSmithKline.
Disclaimer
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
0.5 ABIM MOC Point(s)
Expires: September 29, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is allergists, pulmonologists, primary care physicians, and other health care professionals involved in the management of patients with eosinophilic asthma.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Employ understanding of the prevalence and pathophysiology of eosinophilic asthma, including the role of eosinophils as a biomarker in the management of asthma.
- Apply knowledge of mechanisms of action, frequency, routes of administration, and clinical evidence regarding the safety and efficacy of biologic therapies for the management of eosinophilic asthma.
Activity Description
In this Wheel of Knowledge Challenge interactive quiz, your knowledge will be tested on biologic therapy options for patients with eosinophilic asthma, including mechanisms of action, frequency, routes of administration, and clinical evidence regarding safety and efficacy. Your hosts will also discuss the prevalence and pathophysiology of eosinophilic asthma and the role of eosinophils as a biomarker in asthma management.
Statement of Educational Need
An increasing body of evidence continues to define the presence of severe asthma subtypes that do not respond to conventional therapies. Eosinophilic asthma is an often-severe subtype of asthma, predominantly driven by eosinophilic airway inflammation. Clinical practice guidelines recommend phenotypic assessment and consideration of select add-on biologic therapy for eosinophilic asthma. Biologic therapies that modulate the interleukin (IL)-5 and IL-4/13 signaling pathways offer important maintenance therapy options for patients with eosinophilic asthma inadequately controlled on standard therapy. Awareness of the latest evidence-based strategies for managing eosinophilic asthma will better enable health care professionals to tailor an individualized, targeted treatment approach.
Faculty
Associate Professor, Medicine-Pulmonary
Director, Airways Clinical Research Center
Member, Vice Chair of Research Group
Baylor College of Medicine
Director, Asthma and COPD Clinic
Ben Taub Hospital
Houston, TX
Disclosure:
Consulting Fee: Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi, Teva
Contracted Research: AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Gossamer Bio, Novartis, Sanofi
Professor, Pulmonary & Critical Care Medicine
Director, Mary Parkes Center for Asthma, Allergy & Pulmonary Care
University of Rochester
Rochester, NY
Disclosure:
Contracted Research: GlaxoSmithKline
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.5 Medical Knowledge MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s responsibility
to submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This educational activity is supported by an educational grant from GlaxoSmithKline.
Disclaimer
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Family Medicine Presentations
Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza in High-Risk Patients: Aching for Optimal Treatment
StartActivity Details
0.5 ANCC contact hour(s)
0.5 ACPE contact hour(s)
0.5 ABIM MOC point(s)
Expires: October 17, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients who may be at high risk for influenza-related complications
- Recognize the possible presentations of influenza in high-risk individuals
- Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
- Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza
Activity Description
In this activity, a panel of experts discusses therapeutic options for influenza and reasons why influenza treatment is commonly overlooked even in high-risk patients. Challenges in diagnosing and treating influenza in the era of COVID-19 are highlighted. A high-risk experienced influenza patient shares her experiences with diagnosis and treatment and how influenza affected her quality of life.
Activity Chair
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL
Faculty
Director, Clinical Research Department of Emergency Medicine
University of California San Diego
San Diego, CA
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Christopher J. Coyne, MD, MPH, has a financial relationship with Gilead Pharmaceuticals (Other: Infectious disease screening program).
Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).
Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).
Patient
Patient participating in this activity has no relevant financial
relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical
Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.5 contact hour(s).
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for
0.5 contact hour(s) (0.5 CEUs) of the Accreditation Council for Pharmacy
Education.
(Universal Activity Number – JA4008290-0000-21-004-H01-P)
Type of Activity: Knowledge
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the participant to earn up to 0.5 medical knowledge MOC point(s) in the
American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s
responsibility to submit participant completion information to ACCME for the
purpose of granting ABIM MOC credit.
Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
- Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
- Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
0.5 ANCC contact hour(s)
0.5 ACPE contact hour(s)
0.5 ABIM MOC point(s)
Expires: October 17, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients who may be at high risk for influenza-related complications
- Recognize the possible presentations of influenza in high-risk individuals
- Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
- Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza
Activity Description
In this activity, a panel of experts discusses therapeutic options for influenza and reasons why influenza treatment is commonly overlooked even in high-risk patients. Challenges in diagnosing and treating influenza in the era of COVID-19 are highlighted. A high-risk experienced influenza patient shares her experiences with diagnosis and treatment and how influenza affected her quality of life.
Activity Chair
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL
Faculty
Director, Clinical Research Department of Emergency Medicine
University of California San Diego
San Diego, CA
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Christopher J. Coyne, MD, MPH, has a financial relationship with Gilead Pharmaceuticals (Other: Infectious disease screening program).
Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).
Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).
Patient
Patient participating in this activity has no relevant financial
relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical
Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.5 contact hour(s).
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for
0.5 contact hour(s) (0.5 CEUs) of the Accreditation Council for Pharmacy
Education.
(Universal Activity Number – JA4008290-0000-21-004-H01-P)
Type of Activity: Knowledge
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the participant to earn up to 0.5 medical knowledge MOC point(s) in the
American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s
responsibility to submit participant completion information to ACCME for the
purpose of granting ABIM MOC credit.
Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
- Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
- Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Real-World Perspectives™ Honing Clinical Skills in HIV Treatment: Considering the Patient, the Provider, and the Science – Module 3
StartActivity Details
0.5 Contact Hour(s)
Expires: October 15, 2022
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objectives
After completing this activity, the participant should be better able to:
- Tailor ART regimens according to patient comorbidities, risk factors, polypharmacy, viral level, and treatment history
Activity Description
This activity is the third of a 3-part series based on the proceedings of a CME symposium held in conjunction with IAS 2021. This activity covers treatment selection and emerging options for heavily treatment-resistant patients and Dr. Eric S. Daar discusses clinical trial data and considerations for long-acting injectables. To view the full content from the symposium, please participate in the other modules in this series. In Module 1, Dr. Eric S. Daar reviews the science behind treatment strategies, such as rapid antiretroviral therapy (ART), 2-drug oral and long-acting regimens, and emerging ART options. In Module 2, Dr. Aadia Rana discusses the evidence behind and implementation of rapid ART, both in the United States and globally, and Dr. Seble G. Kassaye discusses tailoring ART in aging patients with comorbidities and the relationship between ART and weight gain.
Faculty
Chief of the Division of HIV Medicine
Harbor-University of California, Los Angeles (UCLA) Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
Head, Infectious Diseases Unit
Research Director of HIV and Infectious Diseases
La Paz Hospital
Associate Professor of Medicine
Autonoma University School of Medicine
Madrid, Spain
Associate Professor of Medicine
Georgetown University
Infectious Disease Physician
Unity Health Care
Washington, District of Columbia
Associate Professor of Medicine
University of Alabama-Birmingham
Associate Scientist
UAB Center for AIDS Research
Birmingham, Alabama
Disclosure of Conflicts of Interest
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.
PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
Eric S. Daar, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare Limited; Contracted Research: Gilead Sciences, Inc., ViiV Healthcare Limited
José R. Arribas, MD: Consulting Fees: Alexza Pharmaceuticals, Eli Lilly and Company, EMD Serono, Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Teva Pharmaceuticals USA, Inc., ViiV Healthcare Limited; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp, ViiV Healthcare Limited; Contracted Research: Gilead Sciences, Inc., ViiV Healthcare Limited
Seble G. Kassaye, MD, MS: Nothing to disclose
Aadia Rana, MD: Nothing to disclose
Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
PIM designates part 3 of this enduring activity for a maximum of 0.5 AMA
PRA Category 1 Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for part 3 of this Continuing Nursing
Education activity is 0.5 contact hour(s).
Instructions for Receiving Credit
In order to receive credit, participants must score at least 75% on the posttest and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Activity Details
0.5 Contact Hour(s)
Expires: October 15, 2022
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objectives
After completing this activity, the participant should be better able to:
- Tailor ART regimens according to patient comorbidities, risk factors, polypharmacy, viral level, and treatment history
Activity Description
This activity is the third of a 3-part series based on the proceedings of a CME symposium held in conjunction with IAS 2021. This activity covers treatment selection and emerging options for heavily treatment-resistant patients and Dr. Eric S. Daar discusses clinical trial data and considerations for long-acting injectables. To view the full content from the symposium, please participate in the other modules in this series. In Module 1, Dr. Eric S. Daar reviews the science behind treatment strategies, such as rapid antiretroviral therapy (ART), 2-drug oral and long-acting regimens, and emerging ART options. In Module 2, Dr. Aadia Rana discusses the evidence behind and implementation of rapid ART, both in the United States and globally, and Dr. Seble G. Kassaye discusses tailoring ART in aging patients with comorbidities and the relationship between ART and weight gain.
Faculty
Chief of the Division of HIV Medicine
Harbor-University of California, Los Angeles (UCLA) Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
Head, Infectious Diseases Unit
Research Director of HIV and Infectious Diseases
La Paz Hospital
Associate Professor of Medicine
Autonoma University School of Medicine
Madrid, Spain
Associate Professor of Medicine
Georgetown University
Infectious Disease Physician
Unity Health Care
Washington, District of Columbia
Associate Professor of Medicine
University of Alabama-Birmingham
Associate Scientist
UAB Center for AIDS Research
Birmingham, Alabama
Disclosure of Conflicts of Interest
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.
PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
Eric S. Daar, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare Limited; Contracted Research: Gilead Sciences, Inc., ViiV Healthcare Limited
José R. Arribas, MD: Consulting Fees: Alexza Pharmaceuticals, Eli Lilly and Company, EMD Serono, Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Teva Pharmaceuticals USA, Inc., ViiV Healthcare Limited; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp, ViiV Healthcare Limited; Contracted Research: Gilead Sciences, Inc., ViiV Healthcare Limited
Seble G. Kassaye, MD, MS: Nothing to disclose
Aadia Rana, MD: Nothing to disclose
Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
PIM designates part 3 of this enduring activity for a maximum of 0.5 AMA
PRA Category 1 Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for part 3 of this Continuing Nursing
Education activity is 0.5 contact hour(s).
Instructions for Receiving Credit
In order to receive credit, participants must score at least 75% on the posttest and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Real-World Perspectives™ Honing Clinical Skills in HIV Treatment: Considering the Patient, the Provider, and the Science – Module 1
StartActivity Details
0.25 Contact Hour(s)
Expires: October 15, 2022
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe the science behind recent advances in HIV treatment
Activity Description
This activity is the first of a 3-part series based on the proceedings of a CME/CE symposium held in conjunction with IAS 2021. Dr. Eric S. Daar covers the science behind treatment strategies, such as rapid antiretroviral therapy (ART), 2-drug oral and long-acting regimens, and emerging ART options. To view the full content from the symposium, please participate in the other modules in this series. In Module 2, Dr. Aadia Rana discusses the evidence behind and implementation of rapid ART, both in the United States and globally, and Dr. Seble G. Kassaye discusses tailoring ART in aging patients with comorbidities and the relationship between ART and weight gain. In Module 3, Dr. José R. Arribas discusses treatment selection and emerging options for heavily treatment-resistant patients and Dr. Eric S. Daar discusses clinical trial data and considerations for long-acting injectables.
Faculty
Chief of the Division of HIV Medicine
Harbor-University of California, Los Angeles (UCLA) Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
Head, Infectious Diseases Unit
Research Director of HIV and Infectious Diseases
La Paz Hospital
Associate Professor of Medicine
Autonoma University School of Medicine
Madrid, Spain
Associate Professor of Medicine
Georgetown University
Infectious Disease Physician
Unity Health Care
Washington, District of Columbia
Associate Professor of Medicine
University of Alabama-Birmingham
Associate Scientist
UAB Center for AIDS Research
Birmingham, Alabama
Disclosure of Conflicts of Interest
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.
PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
Eric S. Daar, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare Limited; Contracted Research: Gilead Sciences, Inc., ViiV Healthcare Limited
José R. Arribas, MD: Consulting Fees: Alexza Pharmaceuticals, Eli Lilly and Company, EMD Serono, Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Teva Pharmaceuticals USA, Inc., ViiV Healthcare Limited; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp, ViiV Healthcare Limited; Contracted Research: Gilead Sciences, Inc., ViiV Healthcare Limited
Seble G. Kassaye, MD, MS: Nothing to disclose
Aadia Rana, MD: Nothing to disclose
Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
PIM designates part 1 of this enduring activity for a maximum of 0.25 AMA
PRA Category 1 Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for part 1 of this Continuing Nursing
Education activity is 0.25 contact hour(s).
Instructions for Receiving Credit
In order to receive credit, participants must score 100% on the posttest and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Activity Details
0.25 Contact Hour(s)
Expires: October 15, 2022
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe the science behind recent advances in HIV treatment
Activity Description
This activity is the first of a 3-part series based on the proceedings of a CME/CE symposium held in conjunction with IAS 2021. Dr. Eric S. Daar covers the science behind treatment strategies, such as rapid antiretroviral therapy (ART), 2-drug oral and long-acting regimens, and emerging ART options. To view the full content from the symposium, please participate in the other modules in this series. In Module 2, Dr. Aadia Rana discusses the evidence behind and implementation of rapid ART, both in the United States and globally, and Dr. Seble G. Kassaye discusses tailoring ART in aging patients with comorbidities and the relationship between ART and weight gain. In Module 3, Dr. José R. Arribas discusses treatment selection and emerging options for heavily treatment-resistant patients and Dr. Eric S. Daar discusses clinical trial data and considerations for long-acting injectables.
Faculty
Chief of the Division of HIV Medicine
Harbor-University of California, Los Angeles (UCLA) Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
Head, Infectious Diseases Unit
Research Director of HIV and Infectious Diseases
La Paz Hospital
Associate Professor of Medicine
Autonoma University School of Medicine
Madrid, Spain
Associate Professor of Medicine
Georgetown University
Infectious Disease Physician
Unity Health Care
Washington, District of Columbia
Associate Professor of Medicine
University of Alabama-Birmingham
Associate Scientist
UAB Center for AIDS Research
Birmingham, Alabama
Disclosure of Conflicts of Interest
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.
PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
Eric S. Daar, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare Limited; Contracted Research: Gilead Sciences, Inc., ViiV Healthcare Limited
José R. Arribas, MD: Consulting Fees: Alexza Pharmaceuticals, Eli Lilly and Company, EMD Serono, Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Teva Pharmaceuticals USA, Inc., ViiV Healthcare Limited; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp, ViiV Healthcare Limited; Contracted Research: Gilead Sciences, Inc., ViiV Healthcare Limited
Seble G. Kassaye, MD, MS: Nothing to disclose
Aadia Rana, MD: Nothing to disclose
Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
PIM designates part 1 of this enduring activity for a maximum of 0.25 AMA
PRA Category 1 Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for part 1 of this Continuing Nursing
Education activity is 0.25 contact hour(s).
Instructions for Receiving Credit
In order to receive credit, participants must score 100% on the posttest and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Real-World Perspectives™ Honing Clinical Skills in HIV Treatment: Considering the Patient, the Provider, and the Science – Module 2
StartActivity Details
0.5 Contact Hour(s)
Expires: October 15, 2022
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objectives
After completing this activity, the participant should be better able to:
- Implement appropriate workflow protocols to optimize rapid ART implementation
- Tailor ART regimens according to patient comorbidities, risk factors, polypharmacy, viral level, and treatment history
Activity Description
This activity is the second of a 3-part series based on the proceedings of a CME symposium held in conjunction with IAS 2021. Dr. Seble G. Kassaye and Dr. Aadia Rana use patient and clinic cases to cover the evidence behind and implementation of rapid antiretroviral therapy (ART), both in the United States and globally, nuances of tailoring ART in aging patients with comorbidities, and the relationship between ART and weight gain. To view the full content from the symposium, please participate in the other modules in this series. In Module 1, Dr. Eric S. Daar reviews the science behind treatment strategies, such as rapid ART, 2-drug oral and long-acting regimens, and emerging ART options. In Module 3, Dr. José R. Arribas discusses treatment selection and emerging options for heavily treatment-resistant patients and Dr. Eric S. Daar discusses clinical trial data and considerations for long-acting injectables.
Faculty
Chief of the Division of HIV Medicine
Harbor-University of California, Los Angeles (UCLA) Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
Head, Infectious Diseases Unit
Research Director of HIV and Infectious Diseases
La Paz Hospital
Associate Professor of Medicine
Autonoma University School of Medicine
Madrid, Spain
Associate Professor of Medicine
Georgetown University
Infectious Disease Physician
Unity Health Care
Washington, District of Columbia
Associate Professor of Medicine
University of Alabama-Birmingham
Associate Scientist
UAB Center for AIDS Research
Birmingham, Alabama
Disclosure of Conflicts of Interest
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.
PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
Eric S. Daar, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare Limited; Contracted Research: Gilead Sciences, Inc., ViiV Healthcare Limited
José R. Arribas, MD: Consulting Fees: Alexza Pharmaceuticals, Eli Lilly and Company, EMD Serono, Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Teva Pharmaceuticals USA, Inc., ViiV Healthcare Limited; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp, ViiV Healthcare Limited; Contracted Research: Gilead Sciences, Inc., ViiV Healthcare Limited
Seble G. Kassaye, MD, MS: Nothing to disclose
Aadia Rana, MD: Nothing to disclose
Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
PIM designates part 2 of this enduring activity for a maximum of 0.5 AMA
PRA Category 1 Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for part 2 of this Continuing Nursing
Education activity is 0.5 contact hour(s).
Instructions for Receiving Credit
In order to receive credit, participants must score at least 75% on the posttest and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Activity Details
0.5 Contact Hour(s)
Expires: October 15, 2022
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objectives
After completing this activity, the participant should be better able to:
- Implement appropriate workflow protocols to optimize rapid ART implementation
- Tailor ART regimens according to patient comorbidities, risk factors, polypharmacy, viral level, and treatment history
Activity Description
This activity is the second of a 3-part series based on the proceedings of a CME symposium held in conjunction with IAS 2021. Dr. Seble G. Kassaye and Dr. Aadia Rana use patient and clinic cases to cover the evidence behind and implementation of rapid antiretroviral therapy (ART), both in the United States and globally, nuances of tailoring ART in aging patients with comorbidities, and the relationship between ART and weight gain. To view the full content from the symposium, please participate in the other modules in this series. In Module 1, Dr. Eric S. Daar reviews the science behind treatment strategies, such as rapid ART, 2-drug oral and long-acting regimens, and emerging ART options. In Module 3, Dr. José R. Arribas discusses treatment selection and emerging options for heavily treatment-resistant patients and Dr. Eric S. Daar discusses clinical trial data and considerations for long-acting injectables.
Faculty
Chief of the Division of HIV Medicine
Harbor-University of California, Los Angeles (UCLA) Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
Head, Infectious Diseases Unit
Research Director of HIV and Infectious Diseases
La Paz Hospital
Associate Professor of Medicine
Autonoma University School of Medicine
Madrid, Spain
Associate Professor of Medicine
Georgetown University
Infectious Disease Physician
Unity Health Care
Washington, District of Columbia
Associate Professor of Medicine
University of Alabama-Birmingham
Associate Scientist
UAB Center for AIDS Research
Birmingham, Alabama
Disclosure of Conflicts of Interest
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.
PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
Eric S. Daar, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare Limited; Contracted Research: Gilead Sciences, Inc., ViiV Healthcare Limited
José R. Arribas, MD: Consulting Fees: Alexza Pharmaceuticals, Eli Lilly and Company, EMD Serono, Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Teva Pharmaceuticals USA, Inc., ViiV Healthcare Limited; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp, ViiV Healthcare Limited; Contracted Research: Gilead Sciences, Inc., ViiV Healthcare Limited
Seble G. Kassaye, MD, MS: Nothing to disclose
Aadia Rana, MD: Nothing to disclose
Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
PIM designates part 2 of this enduring activity for a maximum of 0.5 AMA
PRA Category 1 Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for part 2 of this Continuing Nursing
Education activity is 0.5 contact hour(s).
Instructions for Receiving Credit
In order to receive credit, participants must score at least 75% on the posttest and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza Postexposure Prophylaxis: Don’t Overlook the High-Risk Patient
StartActivity Details
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Expires: October 10, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients who may be at high risk for influenza-related complications
- Recognize the possible presentations of influenza in high-risk individuals
- Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
- Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza
Activity Description
In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.
Activity Chair
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL
Faculty
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).
Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical
Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for
0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy
Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the participant to earn up to 0.25 medical knowledge MOC point(s) in the
American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s
responsibility to submit participant completion information to ACCME for the
purpose of granting ABIM MOC credit.
Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
- Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
- Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Expires: October 10, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients who may be at high risk for influenza-related complications
- Recognize the possible presentations of influenza in high-risk individuals
- Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
- Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza
Activity Description
In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.
Activity Chair
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL
Faculty
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).
Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical
Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for
0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy
Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the participant to earn up to 0.25 medical knowledge MOC point(s) in the
American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s
responsibility to submit participant completion information to ACCME for the
purpose of granting ABIM MOC credit.
Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
- Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
- Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Emergence of Biologics in Eosinophilic Asthma: A Wheel of Knowledge Challenge!
StartActivity Details
0.5 ABIM MOC Point(s)
Expires: September 29, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is allergists, pulmonologists, primary care physicians, and other health care professionals involved in the management of patients with eosinophilic asthma.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Employ understanding of the prevalence and pathophysiology of eosinophilic asthma, including the role of eosinophils as a biomarker in the management of asthma.
- Apply knowledge of mechanisms of action, frequency, routes of administration, and clinical evidence regarding the safety and efficacy of biologic therapies for the management of eosinophilic asthma.
Activity Description
In this Wheel of Knowledge Challenge interactive quiz, your knowledge will be tested on biologic therapy options for patients with eosinophilic asthma, including mechanisms of action, frequency, routes of administration, and clinical evidence regarding safety and efficacy. Your hosts will also discuss the prevalence and pathophysiology of eosinophilic asthma and the role of eosinophils as a biomarker in asthma management.
Statement of Educational Need
An increasing body of evidence continues to define the presence of severe asthma subtypes that do not respond to conventional therapies. Eosinophilic asthma is an often-severe subtype of asthma, predominantly driven by eosinophilic airway inflammation. Clinical practice guidelines recommend phenotypic assessment and consideration of select add-on biologic therapy for eosinophilic asthma. Biologic therapies that modulate the interleukin (IL)-5 and IL-4/13 signaling pathways offer important maintenance therapy options for patients with eosinophilic asthma inadequately controlled on standard therapy. Awareness of the latest evidence-based strategies for managing eosinophilic asthma will better enable health care professionals to tailor an individualized, targeted treatment approach.
Faculty
Associate Professor, Medicine-Pulmonary
Director, Airways Clinical Research Center
Member, Vice Chair of Research Group
Baylor College of Medicine
Director, Asthma and COPD Clinic
Ben Taub Hospital
Houston, TX
Disclosure:
Consulting Fee: Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi, Teva
Contracted Research: AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Gossamer Bio, Novartis, Sanofi
Professor, Pulmonary & Critical Care Medicine
Director, Mary Parkes Center for Asthma, Allergy & Pulmonary Care
University of Rochester
Rochester, NY
Disclosure:
Contracted Research: GlaxoSmithKline
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.5 Medical Knowledge MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s responsibility
to submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This educational activity is supported by an educational grant from GlaxoSmithKline.
Disclaimer
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
0.5 ABIM MOC Point(s)
Expires: September 29, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is allergists, pulmonologists, primary care physicians, and other health care professionals involved in the management of patients with eosinophilic asthma.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Employ understanding of the prevalence and pathophysiology of eosinophilic asthma, including the role of eosinophils as a biomarker in the management of asthma.
- Apply knowledge of mechanisms of action, frequency, routes of administration, and clinical evidence regarding the safety and efficacy of biologic therapies for the management of eosinophilic asthma.
Activity Description
In this Wheel of Knowledge Challenge interactive quiz, your knowledge will be tested on biologic therapy options for patients with eosinophilic asthma, including mechanisms of action, frequency, routes of administration, and clinical evidence regarding safety and efficacy. Your hosts will also discuss the prevalence and pathophysiology of eosinophilic asthma and the role of eosinophils as a biomarker in asthma management.
Statement of Educational Need
An increasing body of evidence continues to define the presence of severe asthma subtypes that do not respond to conventional therapies. Eosinophilic asthma is an often-severe subtype of asthma, predominantly driven by eosinophilic airway inflammation. Clinical practice guidelines recommend phenotypic assessment and consideration of select add-on biologic therapy for eosinophilic asthma. Biologic therapies that modulate the interleukin (IL)-5 and IL-4/13 signaling pathways offer important maintenance therapy options for patients with eosinophilic asthma inadequately controlled on standard therapy. Awareness of the latest evidence-based strategies for managing eosinophilic asthma will better enable health care professionals to tailor an individualized, targeted treatment approach.
Faculty
Associate Professor, Medicine-Pulmonary
Director, Airways Clinical Research Center
Member, Vice Chair of Research Group
Baylor College of Medicine
Director, Asthma and COPD Clinic
Ben Taub Hospital
Houston, TX
Disclosure:
Consulting Fee: Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi, Teva
Contracted Research: AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Gossamer Bio, Novartis, Sanofi
Professor, Pulmonary & Critical Care Medicine
Director, Mary Parkes Center for Asthma, Allergy & Pulmonary Care
University of Rochester
Rochester, NY
Disclosure:
Contracted Research: GlaxoSmithKline
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.5 Medical Knowledge MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s responsibility
to submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This educational activity is supported by an educational grant from GlaxoSmithKline.
Disclaimer
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
W.O.W. Why HOw and When to measure Lipoprotein(a): A Clinically Relevant Cardiovascular Risk Factor
StartActivity Details
1.0 ABIM MOC credit(s)
1.0 Contact Hour(s)
Expires: September 12, 2022
Accredited By
Target Audience
Includes but is not limited to cardiologists, interventional cardiologists, preventative cardiologists, LDL specialists, nurse practitioners, physician assistants, nurses, etc.
Learning Objectives
- Define Lipoprotein(a)
- Describe WHY Lipoprotein(a) should be measured
- Explain HOW to measure Lipoprotein(a)
- Indicate WHEN to measure Lipoprotein(a)
Activity Description
This webinar will cover the principles of why, how and when clinicians should consider measuring Lipoprotein(a) levels. It will be based on the latest available scientific evidence and support the ongoing guidelines/methods being used in the field.
Statement of Educational Need
- Clinicians lack knowledge about why they should measure Lipoprotein(a)
- Clinicians do not know how to measure Lipoprotein(a)
- Clinicians do not recognize when to measure Lipoprotein(a)
Faculty
Professor of Medicine
Division of Cardiovascular Medicine, School of Medicine
Oregon Science & Health University
Portland, Oregon
Disclosure: Akcea
Herbert Irving Assistant Professor of Medicine
Columbia University Medical Center
College of Physicians and Surgeons
New York, New York
Disclosure: Amgen, Inc.
Head of Department of Clinical Biochemistry
Herlev and Gentofte Hospital
Copenhagen University Hospital
Copenhagen, Denmark
Disclosure: None reported relevant to this webinar.
Cardiologist
UC San Diego Health
San Diego, California
Disclosure: Kaneka, Ionis Pharmaceuticals
Conflict of Interest Policy/Disclosure Statement
All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.
Joint Accreditation Statement
In support of improving patient care,
this activity has been planned and implemented by the American Heart
Association. The American Heart Association is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a
maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
MOC Statement
Successful completion of this CE activity, which includes participation in
the evaluation component, enables the participant to earn up to 1.0 MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance
of Certification (MOC) program. Participants will earn MOC points equivalent
to the amount of CE credits claimed for the activity. It is the CE activity
provider’s responsibility to submit participant completion information
to ACCME for the purpose of granting ABIM MOC credit.
AAPA Credit Acceptance Statement – Physician
Assistants
AAPA accepts certificates of participation for educational activities
certified for AMA PRA Category 1 Credit(s)™ from organizations
accredited by ACCME or a recognized state medical society. Physician
assistants may receive a maximum of 1.0 hour of Category I credit for
completing this program.
AANP Credit Acceptance Statement – Nurse
Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1
Credit(s)™ from organizations accredited by the ACCME.
ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact
hours.
Statement of Commercial Support
This activity is supported by an educational grant from Kaneka Corporation.
Disclaimer Statement/Disclosure of Unlabeled Use
When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Contact Information for Questions About the Activity
Please contact Sheila Jackson at the American Heart Association at Sheila.Jackson@heart.org with any questions.
Activity Details
1.0 ABIM MOC credit(s)
1.0 Contact Hour(s)
Expires: September 12, 2022
Accredited By
Target Audience
Includes but is not limited to cardiologists, interventional cardiologists, preventative cardiologists, LDL specialists, nurse practitioners, physician assistants, nurses, etc.
Learning Objectives
- Define Lipoprotein(a)
- Describe WHY Lipoprotein(a) should be measured
- Explain HOW to measure Lipoprotein(a)
- Indicate WHEN to measure Lipoprotein(a)
Activity Description
This webinar will cover the principles of why, how and when clinicians should consider measuring Lipoprotein(a) levels. It will be based on the latest available scientific evidence and support the ongoing guidelines/methods being used in the field.
Statement of Educational Need
- Clinicians lack knowledge about why they should measure Lipoprotein(a)
- Clinicians do not know how to measure Lipoprotein(a)
- Clinicians do not recognize when to measure Lipoprotein(a)
Faculty
Professor of Medicine
Division of Cardiovascular Medicine, School of Medicine
Oregon Science & Health University
Portland, Oregon
Disclosure: Akcea
Herbert Irving Assistant Professor of Medicine
Columbia University Medical Center
College of Physicians and Surgeons
New York, New York
Disclosure: Amgen, Inc.
Head of Department of Clinical Biochemistry
Herlev and Gentofte Hospital
Copenhagen University Hospital
Copenhagen, Denmark
Disclosure: None reported relevant to this webinar.
Cardiologist
UC San Diego Health
San Diego, California
Disclosure: Kaneka, Ionis Pharmaceuticals
Conflict of Interest Policy/Disclosure Statement
All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.
Joint Accreditation Statement
In support of improving patient care,
this activity has been planned and implemented by the American Heart
Association. The American Heart Association is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a
maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
MOC Statement
Successful completion of this CE activity, which includes participation in
the evaluation component, enables the participant to earn up to 1.0 MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance
of Certification (MOC) program. Participants will earn MOC points equivalent
to the amount of CE credits claimed for the activity. It is the CE activity
provider’s responsibility to submit participant completion information
to ACCME for the purpose of granting ABIM MOC credit.
AAPA Credit Acceptance Statement – Physician
Assistants
AAPA accepts certificates of participation for educational activities
certified for AMA PRA Category 1 Credit(s)™ from organizations
accredited by ACCME or a recognized state medical society. Physician
assistants may receive a maximum of 1.0 hour of Category I credit for
completing this program.
AANP Credit Acceptance Statement – Nurse
Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1
Credit(s)™ from organizations accredited by the ACCME.
ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact
hours.
Statement of Commercial Support
This activity is supported by an educational grant from Kaneka Corporation.
Disclaimer Statement/Disclosure of Unlabeled Use
When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Contact Information for Questions About the Activity
Please contact Sheila Jackson at the American Heart Association at Sheila.Jackson@heart.org with any questions.
Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part IV: Patient Cases: Putting Evidence Into Perspective
StartActivity Details
1 contact hour(s)
Expires: June 17, 2022
Accredited By
Target Audience
The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.
Learning Objectives
- Summarize the current guidelines and recommendations for the treatment of PAH
- Develop individualized treatment regimens based on the multidisciplinary approach to care for PAH that takes into account treatment goals, short-and-long-term assessment, and comorbidities in order to improve patient outcomes
Faculty
Professor, Pulmonary and Critical Care Medicine
Associate Chief Quality Officer
UT Southwestern Medical Center
Dallas, TX
Dr. Bartolome discloses the following:
Consulting Fees: Janssen
Investigator, The Lundquist Institute
Professor of Medicine, David Geffen School of Medicine at UCLA
Director, Liu Center for Pulmonary Hypertension, The Lundquist Institute
Torrance, CA
Dr. Oudiz discloses the following:
Consulting Fees: Gilead, Gossamer, Insmed, JnJ, Liquidia, Respira, United
Therapeutics, V-Wave
Fees for Non-CME Services Received Directly from a Commercial Interest: JnJ,
United Therapeutics, V-Wave
Contracted Research: AADi, Gossamer, Insmed, JnJ, Liquidia, United
Therapeutics, V-Wave
Conflict of Interest Policy/Disclosure Statement
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credits commensurate with the extent of their
participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education
activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced
Practice Registered Nurses will be designated on your certificate.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education
activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
This is a knowledge-based activity. Universal Activity Numbers (UAN): #
JA4008162-9999-21-2782-H01-P
For Pharmacists: Upon completing the post-test and the activity evaluation
form, transcript information will be sent to the NABP CPE Monitor Service
within 4 – 6 weeks.
Statement of Commercial Support
Supported by an educational grant from Merck Sharp & Dohme Corp.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For questions about the accreditation of this activity, please visit www.pimed.com.
Activity Details
1 contact hour(s)
Expires: June 17, 2022
Accredited By
Target Audience
The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.
Learning Objectives
- Summarize the current guidelines and recommendations for the treatment of PAH
- Develop individualized treatment regimens based on the multidisciplinary approach to care for PAH that takes into account treatment goals, short-and-long-term assessment, and comorbidities in order to improve patient outcomes
Faculty
Professor, Pulmonary and Critical Care Medicine
Associate Chief Quality Officer
UT Southwestern Medical Center
Dallas, TX
Dr. Bartolome discloses the following:
Consulting Fees: Janssen
Investigator, The Lundquist Institute
Professor of Medicine, David Geffen School of Medicine at UCLA
Director, Liu Center for Pulmonary Hypertension, The Lundquist Institute
Torrance, CA
Dr. Oudiz discloses the following:
Consulting Fees: Gilead, Gossamer, Insmed, JnJ, Liquidia, Respira, United
Therapeutics, V-Wave
Fees for Non-CME Services Received Directly from a Commercial Interest: JnJ,
United Therapeutics, V-Wave
Contracted Research: AADi, Gossamer, Insmed, JnJ, Liquidia, United
Therapeutics, V-Wave
Conflict of Interest Policy/Disclosure Statement
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credits commensurate with the extent of their
participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education
activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced
Practice Registered Nurses will be designated on your certificate.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education
activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
This is a knowledge-based activity. Universal Activity Numbers (UAN): #
JA4008162-9999-21-2782-H01-P
For Pharmacists: Upon completing the post-test and the activity evaluation
form, transcript information will be sent to the NABP CPE Monitor Service
within 4 – 6 weeks.
Statement of Commercial Support
Supported by an educational grant from Merck Sharp & Dohme Corp.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For questions about the accreditation of this activity, please visit www.pimed.com.
Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part I: Screening and Diagnosis of PAH
StartActivity Details
1 contact hour(s)
Expires: June 17, 2022
Accredited By
Target Audience
The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.
Learning Objectives
- Identify patients with PAH based on symptoms, risk factors, and screening strategies outlined in evidence-based guidelines
- Utilize evidence-based diagnostic methods to effectively and timely diagnose PAH patients
Faculty
Professor of Medicine
University of Cincinnati
Pulmonary Hypertension Program
Cincinnati, OH
Dr. Elwing discloses the following:
Consulting Fees: United Therapeutics, Acceleron, Liquidia, Altavant, Bayer,
Gossamer Bio
Contracted Research: Actelion, Acceleron, Reata, United Therapeutics,
Liquidia, Phase Bio, Complexa, Gossamer Bio, Bayer
Centre National de Référence de l’Hypertension Pulmonaire Sévère
Hôpital Bicêtre
Assistance Publique – Hôpitaux de Paris
Université Paris-Saclay
Le Kremlin-Bicêtre, France
Dr. Humbert discloses the following:
Consulting Fees: Acceleron, Bayer, GSK, Janssen, Merck
Contracted Research: Acceleron, Bayer, GSK, Janssen, Merck
Conflict of Interest Policy/Disclosure Statement
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credits commensurate with the extent of their
participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education
activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced
Practice Registered Nurses will be designated on your certificate.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education
activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
This is a knowledge-based activity. Universal Activity Numbers (UAN): #
JA4008162-9999-21-2779-H01-P
For Pharmacists: Upon completing the post-test and the activity evaluation
form, transcript information will be sent to the NABP CPE Monitor Service
within 4 – 6 weeks.
Statement of Commercial Support
Supported by an educational grant from Merck Sharp & Dohme Corp.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For questions about the accreditation of this activity, please visit www.pimed.com.
Activity Details
1 contact hour(s)
Expires: June 17, 2022
Accredited By
Target Audience
The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.
Learning Objectives
- Identify patients with PAH based on symptoms, risk factors, and screening strategies outlined in evidence-based guidelines
- Utilize evidence-based diagnostic methods to effectively and timely diagnose PAH patients
Faculty
Professor of Medicine
University of Cincinnati
Pulmonary Hypertension Program
Cincinnati, OH
Dr. Elwing discloses the following:
Consulting Fees: United Therapeutics, Acceleron, Liquidia, Altavant, Bayer,
Gossamer Bio
Contracted Research: Actelion, Acceleron, Reata, United Therapeutics,
Liquidia, Phase Bio, Complexa, Gossamer Bio, Bayer
Centre National de Référence de l’Hypertension Pulmonaire Sévère
Hôpital Bicêtre
Assistance Publique – Hôpitaux de Paris
Université Paris-Saclay
Le Kremlin-Bicêtre, France
Dr. Humbert discloses the following:
Consulting Fees: Acceleron, Bayer, GSK, Janssen, Merck
Contracted Research: Acceleron, Bayer, GSK, Janssen, Merck
Conflict of Interest Policy/Disclosure Statement
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credits commensurate with the extent of their
participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education
activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced
Practice Registered Nurses will be designated on your certificate.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education
activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
This is a knowledge-based activity. Universal Activity Numbers (UAN): #
JA4008162-9999-21-2779-H01-P
For Pharmacists: Upon completing the post-test and the activity evaluation
form, transcript information will be sent to the NABP CPE Monitor Service
within 4 – 6 weeks.
Statement of Commercial Support
Supported by an educational grant from Merck Sharp & Dohme Corp.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For questions about the accreditation of this activity, please visit www.pimed.com.
Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part II: PAH Treatment - Goals, Therapeutic Options, and Guidelines
StartActivity Details
1 contact hour(s)
Expires: June 17, 2022
Accredited By
Target Audience
The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.
Learning Objectives
- Incorporate risk stratification methods for selecting and modifying therapy in patients with PAH
- Evaluate the efficacy and safety of current and emerging therapeutic options for PAH
- Review the evidence for initiating combination therapy in patients with PAH
Faculty
Professore Ordinario di Cardiologia
Direttore U.O.C. di Cardiologia, IRCCS-Policlinico di S.Orsola, Bologna
Direttore della Scuola di Specializzazione in
Malattie dell’Apparato Cardiovascolare
Bologna, Italy
Dr. Galiè discloses the following:
Consulting Fees: Janssen, Actelion, Ferrer, Pfizer
Contracted Research: Janssen
French Reference Center for PH
Emeritus Professor University Paris-Saclay
Paris, France
Dr. Simonneau discloses the following:
Consulting Fees: Actelion, Bayer, MSA
Fees for Non-CME Services Received Directly from a Commercial Interest:
Actelion, Bayer, MSA
Conflict of Interest Policy/Disclosure Statement
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credits commensurate with the extent of their
participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education
activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced
Practice Registered Nurses will be designated on your certificate.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education
activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
This is a knowledge-based activity. Universal Activity Numbers (UAN): #
JA4008162-9999-21-2780-H01-P
For Pharmacists: Upon completing the post-test and the activity evaluation
form, transcript information will be sent to the NABP CPE Monitor Service
within 4 – 6 weeks.
Statement of Commercial Support
Supported by an educational grant from Merck Sharp & Dohme Corp.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For questions about the accreditation of this activity, please visit www.pimed.com.
Activity Details
1 contact hour(s)
Expires: June 17, 2022
Accredited By
Target Audience
The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.
Learning Objectives
- Incorporate risk stratification methods for selecting and modifying therapy in patients with PAH
- Evaluate the efficacy and safety of current and emerging therapeutic options for PAH
- Review the evidence for initiating combination therapy in patients with PAH
Faculty
Professore Ordinario di Cardiologia
Direttore U.O.C. di Cardiologia, IRCCS-Policlinico di S.Orsola, Bologna
Direttore della Scuola di Specializzazione in
Malattie dell’Apparato Cardiovascolare
Bologna, Italy
Dr. Galiè discloses the following:
Consulting Fees: Janssen, Actelion, Ferrer, Pfizer
Contracted Research: Janssen
French Reference Center for PH
Emeritus Professor University Paris-Saclay
Paris, France
Dr. Simonneau discloses the following:
Consulting Fees: Actelion, Bayer, MSA
Fees for Non-CME Services Received Directly from a Commercial Interest:
Actelion, Bayer, MSA
Conflict of Interest Policy/Disclosure Statement
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credits commensurate with the extent of their
participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education
activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced
Practice Registered Nurses will be designated on your certificate.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education
activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
This is a knowledge-based activity. Universal Activity Numbers (UAN): #
JA4008162-9999-21-2780-H01-P
For Pharmacists: Upon completing the post-test and the activity evaluation
form, transcript information will be sent to the NABP CPE Monitor Service
within 4 – 6 weeks.
Statement of Commercial Support
Supported by an educational grant from Merck Sharp & Dohme Corp.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For questions about the accreditation of this activity, please visit www.pimed.com.